New antibody drug takes aim at Hard-to-Treat lymphoma

NCT ID NCT04594642

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called AZD0486 in about 226 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and follicular lymphoma. The drug is a bispecific antibody designed to help the body's immune T-cells recognize and kill cancer cells. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0486 (a bispecific antibody that helps immune cells attack cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for people with B-cell non-Hodgkin lymphoma who have not responded to other therapies.
What could go wrong: This is an early phase 1 trial, so the main goal is safety, not proof of effectiveness. Side effects like cytokine release syndrome and nerve problems are possible, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma high grade B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKIN LYMPHOMA DIFFUSE LARGE B-CELL LYMPHOMA FOLLICULAR LYMPHOMA HIGH-GRADE B-CELL LYMPHOMA

Contacts and locations

Locations

Research Site

Tampa, Florida, 33612, United States
Research Site

Louisville, Kentucky, 40207, United States
Research Site

New Brunswick, New Jersey, 08901, United States
Research Site

Charlotte, North Carolina, 28204, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Pittsburgh, Pennsylvania, 15237, United States
Research Site

Austin, Texas, 78704, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Milwaukee, Wisconsin, 53226, United States
Research Site

Heidelberg, 3084, Australia
Research Site

Hobart, 7000, Australia
Research Site

Melbourne, 3004, Australia
Research Site

Chūōku, 104-0045, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Nagoya, 460-0001, Japan
Research Site

Yamagata, 990-9585, Japan
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06591, South Korea
Research Site

Seoul, 120-752, South Korea
Research Site

Kaohsiung City, 833401, Taiwan
Research Site

Kweishan, 333, Taiwan
Research Site

Tainan, 704, Taiwan
Research Site

Taipei, 10002, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.